California Public Employees Retirement System Sells 8,307 Shares of Ralliant Corporation $RAL

California Public Employees Retirement System reduced its holdings in Ralliant Corporation (NYSE:RAL) by 4.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 185,683 shares of the company’s stock after selling 8,307 shares during the quarter. California Public Employees Retirement System owned approximately 0.17% of Ralliant worth $7,723,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of RAL. Danske Bank A S bought a new stake in shares of Ralliant in the fourth quarter worth $25,000. Allworth Financial LP raised its position in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the last quarter. V Square Quantitative Management LLC acquired a new position in Ralliant during the 4th quarter worth about $26,000. Palisade Asset Management LLC acquired a new position in Ralliant during the 3rd quarter worth about $26,000. Finally, Rothschild Investment LLC grew its position in shares of Ralliant by 98.1% in the 4th quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after buying an additional 303 shares during the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada increased their price target on Ralliant from $64.00 to $71.00 and gave the company a “sector perform” rating in a research note on Thursday, July 16th. Zacks Research raised Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Citigroup upped their target price on Ralliant from $70.00 to $81.00 and gave the company a “buy” rating in a report on Monday, July 13th. Oppenheimer increased their target price on shares of Ralliant from $50.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, May 13th. Finally, Evercore assumed coverage on shares of Ralliant in a research report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Ralliant has a consensus rating of “Moderate Buy” and an average target price of $73.00.

Ralliant Stock Performance

RAL stock opened at $69.55 on Monday. The firm has a market cap of $7.78 billion and a PE ratio of -6.36. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The stock has a 50-day moving average price of $66.43 and a 200-day moving average price of $53.81. Ralliant Corporation has a 1-year low of $37.27 and a 1-year high of $75.41.

Ralliant (NYSE:RAL) last announced its earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. The business’s revenue for the quarter was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, equities research analysts expect that Ralliant Corporation will post 2.64 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s payout ratio is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.